Evaluation de l'interet d'un dosage des anticorps anti-cetuximab dans la prise en charge therapeutique des patients presentant un cancer colique ou des voies aero-digestives superieures et candidats a un traitement par cetuximab

Trial Profile

Evaluation de l'interet d'un dosage des anticorps anti-cetuximab dans la prise en charge therapeutique des patients presentant un cancer colique ou des voies aero-digestives superieures et candidats a un traitement par cetuximab

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2015

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colon cancer; Head and neck cancer
  • Focus Adverse reactions
  • Acronyms IgES
  • Most Recent Events

    • 28 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top